SanegeneBio Receives NMPA Approval to Initiate a Clinical Trial of SGB-9768 for PNH and aHUS

BOSTON, SHANGHAI, and SUZHOU – May 19, 2026, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced that China’s National Medical Products Administration (NMPA) has approved a new clinical trial application (CTA) for SGB-9768 in complement-mediated hematologic disorders, including Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). SGB-9768 had previously received CTA […] The post SanegeneBio Receives NMPA Approval to Initiate a Clinical Trial of SGB-9768 for PNH and aHUS appeared first on SanegeneBio .